These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 29707288)

  • 1. Negative impact of ratio of the microvascular area to tumor area on the response to EGFR-TKI in non-small cell lung cancer with an
    Anai M; Saruwatari K; Imamura K; Fujino K; Jodai T; Sakata S; Iyama S; Tomita Y; Saeki S; Ichiyasu H; Ikeda K; Suzuki M; Sakagami T
    J Thorac Dis; 2024 Feb; 16(2):1151-1160. PubMed ID: 38505064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of PNA‑sequencing as a complementary test for EGFR mutation analysis in human lung cancer.
    Chen YL; Lin CC; Yu YT; Chen WL; Yang SC; Huang W; Su WC; Chow NH; Ho CL
    Oncol Lett; 2023 Dec; 26(6):539. PubMed ID: 38020305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissecting the genetic variations associated with response to first-line chemotherapy in patients with small cell lung cancer: a retrospective cohort study.
    Zhang Y; Hao Y; Pan H; Zheng H; Zhou J
    J Thorac Dis; 2023 Dec; 15(12):7013-7023. PubMed ID: 38249933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. To err is human, to not learn from human error is dangerous.
    Quick J
    J Perioper Pract; 2023 Oct; 33(10):295. PubMed ID: 37799040
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumor marker-based RecistTM is superior to RECIST as criteria to predict the long-term benefits of targeted therapy in advanced non-small-cell lung cancer with driver gene mutations.
    Xiong K; Yang Y; Yang Y; Wang Z; Liu Y; Duo H; Yuan X; Xiao Y; Xiao H; Yang X
    Neoplasia; 2024 Jul; 53():101006. PubMed ID: 38761505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis.
    Melosky B; Kambartel K; Häntschel M; Bennetts M; Nickens DJ; Brinkmann J; Kayser A; Moran M; Cappuzzo F
    Mol Diagn Ther; 2022 Jan; 26(1):7-18. PubMed ID: 34813053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A CT-derived deep neural network predicts for programmed death ligand-1 expression status in advanced lung adenocarcinomas.
    Zhu Y; Liu YL; Feng Y; Yang XY; Zhang J; Chang DD; Wu X; Tian X; Tang KJ; Xie CM; Guo YB; Feng ST; Ke ZF
    Ann Transl Med; 2020 Aug; 8(15):930. PubMed ID: 32953730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations.
    Hayashi H; Nadal E; Gray JE; Ardizzoni A; Caria N; Puri T; Grohe C
    Clin Lung Cancer; 2022 Jan; 23(1):e69-e82. PubMed ID: 34865963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.
    Zhai H; Zhong W; Yang X; Wu YL
    Transl Lung Cancer Res; 2015 Feb; 4(1):82-93. PubMed ID: 25806348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early radiological response as predictor of overall survival in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor mutations.
    Salvador-Coloma C; Lorente D; Palanca S; Simarro J; Mancheño N; Sandoval J; Lahoz A; Juan Ó
    J Thorac Dis; 2018 Mar; 10(3):1386-1393. PubMed ID: 29707288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
    Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
    Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations: A prospective study.
    Chang JW; Hou MM; Hsieh JJ; Cheung YC; Wang HM; Chen JS; Wang CH; Chen CH; Yeh KY; Ou LY; Hsieh CH; Wu HD; Chen YT; Chang IC; Huang SF
    Biomed J; 2015; 38(3):221-8. PubMed ID: 25179728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
    Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
    Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.
    Yoshida T; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y; Goto K
    Lung Cancer; 2015 Dec; 90(3):477-83. PubMed ID: 26604031
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.